Wave Life Sciences Regains Full Rights to WVE-006, Plans Accelerated FDA Engagement for AATD Therapy

summarizeSummary

Wave Life Sciences has regained full rights to its lead AATD therapeutic candidate, WVE-006, from GSK and plans to pursue an accelerated FDA approval pathway, enhancing its control over a key asset.

check_boxKey Events

• Regains Full Rights to WVE-006

  Wave Life Sciences has reacquired full global rights to WVE-006, an investigational RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD), from GSK.

• Accelerated Regulatory Pathway Planned

  The company plans to accelerate its registrational strategy for WVE-006, including engaging the FDA on a potential accelerated approval pathway, with regulatory feedback anticipated mid-2026.

• WVE-006 Targets Rare Disease

  WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of AATD, a rare condition affecting approximately 200,000 individuals in the U.S. and Europe, with no currently approved therapies addressing both lung and liver manifestations.

• Clinical Data Updates Expected

  Data from the 400 mg multidose cohort of the RestorAATion-2 clinical trial remain on track for Q1 2026, with data from the 600 mg cohorts expected later in 2026.

auto_awesomeAnalysis

This 8-K announces Wave Life Sciences has regained full control of WVE-006, its investigational RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD), from GSK. This strategic move allows Wave to accelerate its registrational strategy, including engaging the FDA on a potential accelerated approval pathway, with feedback expected mid-2026. WVE-006 is a first-in-class candidate targeting the root cause of AATD, a rare disease with significant unmet needs, and aims to address both lung and liver manifestations. The company also confirmed its ongoing and expanding research collaboration with GSK, with a fourth program selected, and reiterated its cash runway into Q3 2028. This development enhances Wave's control over a key pipeline asset and potentially expedites its path to market, offering a significant positive signal for investors.